Home » Gilead’s Magrolimab Grabs Breakthrough Therapy Designation for Myelodysplastic Syndrome
Gilead’s Magrolimab Grabs Breakthrough Therapy Designation for Myelodysplastic Syndrome
The FDA has granted a Breakthrough Therapy designation to Gilead Sciences’ investigational monoclonal antibody, magrolimab, for the treatment of newly diagnosed myelodysplastic syndrome (MDS), a group of cancers linked to abnormal blood cells.
The designation was based on the results of a phase 1b trial, in which 91 percent of patients treated with magrolimab plus azacitidine achieved a response, and 42 percent achieved a complete remission.
The agency previously granted magrolimab Fast Track and Orphan Drug designations for the treatment of MDS.
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct